Wedbush analyst Robert Driscoll raised the firm’s price target on Elevation Oncology to $8 from $5 and keeps an Outperform rating on the shares. The firm notes Elevation reported Q4/FY23 results, and remains on track to provide an update on its ongoing Phase 1 trial of EO-3021, an ADC targeting Claudin 18.2, in mid-2024, with additional data in the first half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELEV:
- Elevation Oncology reports Q4 EPS (19c), consensus (24c)
- GoodRx upgraded, Fisker downgraded: Wall Street’s top analyst calls
- Elevation Oncology initiated with an Outperform at JMP Securities
- Elevation Oncology doses first patient in Japan in Phase 1 trial of EO-3021
- Elevation Oncology price target raised to $6 from $1.50 at H.C. Wainwright
